Skip to main content
. 2022 Mar 14;10(3):e004129. doi: 10.1136/jitc-2021-004129

Figure 1.

Figure 1

LTX-315 synergizes with PD-L1-targeted therapy in pancreatic cancer. (A–G) The combination of LTX-315 and PD-L1-targeted therapy inhibits pancreatic tumor growth. KPC cells were s.c. inoculated into immunocompetent mice (n=5). Growth curves of tumors were recorded at the indicated time points (A). Representative images of tumor weight (B) and tumors (C) were individually recorded at the experimental endpoints. Representative images of TILs are individually shown (D–F) and further quantified (G). (H–N) The combination of LTX-315 and PD-1-targeted therapy inhibits pancreatic tumor growth. KPC cells were s.c. inoculated into immunocompetent mice (n=5). Growth curves of tumors were recorded at the indicated time points (H). Representative images of tumor weight (I) and tumors (J) were individually recorded at the experimental endpoints. Representative images of TILs are individually shown (K–M) and further quantified (N). Results are presented as mean±SD of one representative experiment. *p<0.05, **p<0.01, ***p<0.001 by a two-tailed t-test; INF, interferon; NS, not significant; PD-L1, programmed cell death ligand 1; s.c., subcutaneous; TILs, tumor-infiltrating lymphocytes.